<DOC>
	<DOCNO>NCT00770822</DOCNO>
	<brief_summary>This study compare high intensity focus ultrasound standard brachytherapy treatment primary , organ confine prostate cancer .</brief_summary>
	<brief_title>Clinical Study SonablateÂ® 500 Treat Localized ( T1c/T2a ) Prostate Cancer</brief_title>
	<detailed_description>The propose study prospective , non-randomized concurrently control study . The active treatment arm use HIFU procedure Sonablate device . The control arm use brachytherapy procedure . The safety effectiveness Sonablate arm compare brachytherapy arm . The control arm study conduct clinical site different Sonablate arm .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>T1c T2a carcinoma prostate confirm biopsy ; life expectancy 5 ( five ) year ; prostate biopsy 10 ( ten ) core biopsy ; Gleason score 6 ( six ) less ; serum Prostate Specific Antigen ( PSA ) 10 ( ten ) ng/ml less ; prostate volume le 40 ( Forty ) cc ; distance Anterior capsule surface Posterior capsule surface ( AP Diameter ) 40 ( Forty ) cm le ; inform consent treatment study 24 month posttreatment followup men previous definitive treatment prostate cancer ; evidence metastatic disease and/or previous positive bonescan , previous diagnosis treatment cancer within last 5 ( five ) year ; prior hormonal therapy prostate cancer ( include bilateral orchiectomy ) ; inability tolerate transrectal ultrasound ; active urinary tract infection ; functional bladder problem ; prior significant rectal surgery ; intraprostatic calcification great 1 ( One ) cm diameter ; interest future fertility ; prostatic surgery/procedure ( except biopsy ) within 1 ( One ) year ; large median lobe prostate ; use medication affect PSA within 2 ( Two ) month ( e.g . finasteride , saw palmetto ) ; current bladder cancer , urethral stricture , bladder neck contracture ; urinary tract and/or rectal fistula ; rectal fibrosis/stenosis ; anomaly rectal anatomy mucus membrane ; prostate seroma/abcess ; prostatitis ; compromise renal function upper urinary tract disease secondary urinary obstruction ; bleed disorders/coagulopathy base measure PT PTT ; implant prostate within 1 ( One ) cm prostate ; zip code primary residence subject great 200 ( Two hundred ) mile clinical site transportation would hinder completion study</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Primary</keyword>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Primary T1c/T2a organ confine prostate cancer</keyword>
	<keyword>organ-confined</keyword>
</DOC>